Compare Bristol-Myers Squibb Co (BMY) vs Nvidia Corp (NVDA) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

NVIDIA (NVDA) trades at $203.53, down 3.52% over the past 24 hours. The stock exhibits a bullish technical signal with strong moving average alignment, while oscillators remain neutral. Fundamentally, the company reported record revenue of $130.50 billion in 2025, with a net income margin of 62.97% and robust cash flow from operations of $64.09 billion. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.87 surpassing the $1.76 estimate. The upcoming Q2 2026 earnings report, expected at $2.09 EPS, is a key near-term catalyst.

The outlook for NVDA remains positive, driven by sustained AI chip demand and strong execution, though risks include heightened competition and market volatility. Analyst consensus is strongly bullish with a $325.86 price target, implying significant upside. Investors should weigh the company's exceptional profitability and growth trajectory against valuation multiples that reflect high expectations.